Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | |
|---|---|---|---|---|---|
| Sales | 2,537.14 | 2,459.46 | 2,658.44 | 2,100.92 | 2,031.64 |
| Operating profit | 540.53 | 513.93 | 879.49 | 617.37 | 585.50 |
| Interest | 10.23 | 6.44 | 8.42 | 13.90 | 11.29 |
| Gross profit | 576.83 | 510.93 | 874.07 | 734.77 | 577.67 |
| EPS (Rs) | 22.64 | 17.76 | 33.93 | 28.94 | 22.49 |
Half yearly
results in details
| Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | |
|---|---|---|---|---|---|
| Other income | 46.53 | 3.45 | 3.00 | 131.30 | 3.46 |
| Stock adjustment | 7.04 | 11.37 | -25.97 | -76.88 | -99.62 |
| Raw material | 577.69 | 534.06 | 579.59 | 506.35 | 471.78 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 499.80 | 528.39 | 499.73 | 409.09 | 397.28 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 912.09 | 871.71 | 725.60 | 644.99 | 676.70 |
| Provisions made | - | - | - | - | - |
| Depreciation | 91.29 | 88.03 | 72.55 | 70.66 | 65.00 |
| Taxation | 40.60 | 73.86 | 134.59 | 108.62 | 88.76 |
| Net profit / loss | 444.95 | 349.05 | 666.93 | 545.49 | 423.91 |
| Extra ordinary item | - | - | - | -10.00 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 39.31 | 39.31 | 39.31 | 37.70 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 21.30 | 20.90 | 33.08 | 29.39 | 28.82 |
| GPM (%) | 22.33 | 20.75 | 32.84 | 32.92 | 28.39 |
| NPM (%) | 17.22 | 14.17 | 25.06 | 24.44 | 20.83 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis